Although TNF antagonists have been the mainstay for the treatment rheumatoid arthritis, new venues of therapeutic strategies, such as the induction of immune tolerance24,25, blockade of other inflammatory cytokines such as GM-CSF signaling pathways26,27 and immune co-stimulators such as OX40L28, are being explored. This evidence concerns the gene CSF2 and rheumatoid arthritis.